SCHEMBL1344741

SCHEMBL1344741

N#Cc1cccc(CC(=O)O)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
NOTUM Q6P988 1/20 0.42
CXCL8 P10145 3/20 0.41
FFAR1 O14842 1/20 0.40
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
MMP12 P39900 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
DUSP3 P51452 1/20 0.39
PTPN5 P54829 1/20 0.39
PTPN11 Q06124 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
GRIN1 Q05586 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15155403 0.85 NOTUM (0.38) NOTUMFFAR1GRIN1GRIN2AKDM4E
SCHEMBL15196732 0.84 RXRA (0.42) AKR1B1TDP1NOTUMCXCL8FFAR1
SCHEMBL3974171 0.82 AKR1B1 (0.55) AKR1B1TDP1CXCL8FFAR1KDM4E
SCHEMBL6034698 0.81 AKR1B1 (0.50) AKR1B1TDP1CXCL8FFAR1MMP1
SCHEMBL14660849 0.79 XDH (0.48) AKR1B1TDP1CXCL8FFAR1DUSP3
SCHEMBL14660830 0.79 P2RX7 (0.50) AKR1B1TDP1CXCL8FFAR1DUSP3
SCHEMBL15018240 0.78 NOTUM (0.36) TDP1NOTUMGRIN1GRIN2AMAPT
SCHEMBL15018243 0.78 PTGDR2 (0.41) TDP1NOTUMGRIN1GRIN2APTGDR2
SCHEMBL30415085 0.78 PTGDR2 (0.41) TDP1NOTUMGRIN1GRIN2APTGDR2
SCHEMBL12648422 0.78 GABRA1 (0.40) TDP1NOTUMGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063064-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2011-11-22 US disclosed
EP-2057125-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2011-03-30 EP disclosed
US-20110059975-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS KENNEDY-SMITH JOSHUA 2011-03-10 US disclosed
US-7713974-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2010-05-11 US disclosed
EP-2057125-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-05-13 EP disclosed
US-20080045511-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-02-21 US disclosed
WO-2008019968-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045511-A1 Non-nucleoside reverse transcriptase inhibitors ADORA2B, ADORA1, ADORA3 AKR1B1 10/4885TDP1 750/4885NOTUM 1411/4885
US-20110059975-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RPIA, ADORA2B, NQO2 AKR1B1 26/4885TDP1 916/4885NOTUM 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.